Facing persistent and potentially insurmountable headwinds from regulators, Illumina (NASDAQ:ILMN) and Pacific Biosciences of California (NASDAQ:PACB) have mutually agreed to terminate their merger agreement announced on November 1, 2018.
Under the terms of the contract, Illumina will pay Pacific Bio a $98M termination fee.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.